Comparative Effects of BBT and Active Cycle of Breathing Technique on Dyspnea and Quality of Life in COPD

COPD Clinical Trial

Official title:

Comparative Effects of BBT and Active Cycle of Breathing Technique on Dyspnea and Quality of Life in COPD

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05947253
• Other study ID #: REC/RCR & AHS/22/0318
• Status: Recruiting
• Phase: N/A
• Start date: May 15, 2023
• Est. completion date: December 15, 2023

Study information

• Verified date: July 2023
• Source: Riphah International University
• Contact: Iqbal Tariq, PHD
• Phone: O3338236752
• Email: iqbal.tariq[@]riphah.edu.pk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comparative effects of Butyeko breathing technique and Active Cycle of Breathing technique on dyspnea and quality of life in patients with chronic obstructive pulmonary disease

Description:

A comparative study to determine the effects of butyeko breathing techniques and Active Cycle of Breathing technique on dyspnea and quality of life in patients with chronic obstructive pulmonary disease. As few researches on Butyeko breathing techniques are still present on COPD most of them are on asthma. The goal of the Butyeko Method is to improve breathing patterns, as indicated by achieving a higher breath hold time (control pause). Every five seconds improvement to the control pause, results in an alleviation of breathing difficulty and improved control of COPD The Butyeko method is a purported method of "retraining" the body's breathing pattern to correct for the presumed chronic hyperventilation and hypocapnea, and thereby treat or cure the body of these medical problems. Patients with chronic obstructive pulmonary disease (COPD) often suffer from expectoration. To address this problem, active cycle of breathing techniques (ACBT) can be applied in patients of COPD. In our study daily Butyeko breathing exercise and active cycle of breathing technique session of 30 to 35 minutes will be given to patients and effects of both techniques will be compared.

A randomized clinical trial will be conducted using convenient sampling or randomized sampling technique in population of chronic obstructive pulmonary disease (COPD).Total sample size will be of 40 and two Groups will be made Group A 20 participants received Buyteko breathing technique and Groups B 20 participants received Active cycle of breathing technique. Data will be collected by using Borg's dyspnea scale, St.George Respiratory questionnaire and by pulmonary function testing. Data will be collected from pulmonary ward Jinnah hospital Lahore whole study will take total duration of 10 months and data will be analyzed using latest version of SPSS-25 software.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 15, 2023
• Est. primary completion date: October 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of COPD confirmed by smoking history.

• PFT showing irreversible airflow limitation.

• Patients hemodynamically stable.

• Males and females.

• Patients capable of completing IPAQ questionnaire

Exclusion Criteria:

• Evidence of unstable cardiac disease, Pulmonale decompensation

• Disabling diseases which prevented participation in the exercise program, such as orthopedic inabilities or peripheral vascular disease.

• Systemic illness.

• Resting O2 saturation <90% with room air breathing and Patient with viral infection

Related Conditions & MeSH terms

• COPD
• Dyspnea

Intervention

Other:
• Buyteko breathing technique
group A 20 participants received Buyteko breathing technique 2 session for 3 weeks
• active cycle of breathing technique
Group B 20 participants received active cycle of breathing technique 2 session for 3 weeks

Locations

Country	Name	City	State
Pakistan	Pulmonary ward Jinnah hospital Lahore.	Lahore	Punjab

Sponsors (1)

Lead Sponsor	Collaborator
Riphah International University

Country where clinical trial is conducted

Pakistan, 

References & Publications (6)

Fazleen A, Wilkinson T. Early COPD: current evidence for diagnosis and management. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620942128. doi: 10.1177/1753466620942128. — View Citation

Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 2006 Sep;3(7):619-23. doi: 10.1513/pats.200603-093SS. — View Citation

Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006 Feb;27(2):397-412. doi: 10.1183/09031936.06.00025805. No abstract available. — View Citation

May SM, Li JT. Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. Allergy Asthma Proc. 2015 Jan-Feb;36(1):4-10. doi: 10.2500/aap.2015.36.3812. — View Citation

Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014 Aug 27;9:871-88. doi: 10.2147/COPD.S49621. eCollection 2014. — View Citation

Vogelmeier CF, Roman-Rodriguez M, Singh D, Han MK, Rodriguez-Roisin R, Ferguson GT. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med. 2020 May;166:105938. doi: 10.1016/j.rmed.2020.105938. Epub 2020 Mar 21. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Borg's dyspnea scale.	For the measurement of dyspnea The Modified Borg Dyspnea Scale (MBS) is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered during six-minute walk testing (6MWT	4 weeks
Primary	Spirometry	Spirometry is the most common of the pulmonary function tests. It measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.; Spirometry is helpful in assessing breathing patterns that identify conditions such as asthma, Chronic obstructive pulmonary disease	4 weeks